Seelos Therapeutics Inc

SEEL NASDAQ
2.110
-0.150
-6.64%
After Hours: 2.120 +0.01 +0.47% 17:13 06/19 EDT
Open
2.240
Prev Close
2.260
High
2.284
Low
2.100
Volume
364.64K
Avg Vol (3M)
2.05M
52 Week High
15.00
52 Week Low
1.320
% Turnover
1.71%
Market Cap
44.89M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Seelos Therapeutics Inc SEEL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
MORE >

Recently

Name
Price
%Change